Skip to Content


Advisory Committee; Renewals

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble


Food and Drug Administration, HHS.




The Food and Drug Administration (FDA) is announcing the renewal of certain FDA advisory committees by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the charters of the committees listed in table 1 of this document for an additional 2 years beyond charter expiration date. The new charters will be in effect until the dates of expiration listed in table 1. This notice is issued under the Federal Advisory Committee Act of October 6, 1972 (Public Law 92-463 (5 U.S.C. app. 2)).


Authority for these committees will expire on the dates indicated in table 1 of this document unless the Commissioner formally determines that renewal is in the public interest.

Table 1.

Name of committeeDate of expiration
Anesthetic and Life Support Drugs Advisory CommitteeMay 1, 2006.
Blood Products Advisory CommitteeMay 13, 2006.
Pulmonary-Allergy Drugs Advisory CommitteeMay 30, 2006.
Drug Safety and Risk Management Advisory CommitteeMay 31, 2006.
Science Advisory Board to the National Center for Toxicological ResearchJune 2, 2006.
Peripheral and Central Nervous System Drugs Advisory CommitteeJune 4, 2006.
Psychopharmacologic Drugs Advisory CommitteeJune 4, 2006.
Transmissible Spongiform Encephalopathies Advisory CommitteeJune 9, 2006.
Science Board to the Food and Drug AdministrationJune 26, 2006.
Allergenic Products Advisory CommitteeJuly 9, 2006.
Cardiovascular and Renal Drugs Advisory CommitteeAugust 27, 2006.
Endocrinologic and Metabolic Drugs Advisory CommitteeAugust 27, 2006.
Oncologic Drugs Advisory CommitteeSeptember 1, 2006.
Anti-Infective Drugs Advisory CommitteeOctober 7, 2006.
Dermatologic and Ophthalmic Drugs Advisory CommitteeOctober 7, 2006.
Cellular, Tissue, and Gene Therapies Advisory Committee (formerly Biological Response Modifiers Advisory Committee)October 28, 2006.
Start Further Info


Linda A. Sherman, Advisory Committee Oversight and Management Staff (HF-4), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1220.

End Further Info Start Signature

Dated: October 29, 2004.

Sheila Dearybury Walcoff,

Associate Commissioner for External Relations.

End Signature End Preamble

[FR Doc. 04-24842 Filed 11-5-04; 8:45 am]